美通社

2024-10-09 23:37

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufacture. Centivax is developing Cent-Flu, a universal influenza vaccine, consisting of a proprietary multivalent mixture of 22 unique mRNA transcripts delivered as a lipid nanoparticle (LNP) encapsulated mRNA vaccine. In vivo, the vaccine has been demonstrated to convey protection against current, past, and future influenza strains. BioCina will provide proven expertise in the selection of optimal plasmid manufacturing cell lines, Master Cell Bank (MCB) and plasmid manufacturing, to support Centivax's progression to First-in-Human clinical trials.

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine.
Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine.

 BioCina's Chief Executive Officer, Mark W. Womack stated, "We're privileged to support Centivax's breakthrough approach to sustained flu prevention and we couldn't be more excited to be their partner of choice to initiate cGMP manufacturing, thus advancing the journey to bring such an important vaccine to market. This is a tremendous opportunity for the BioCina Team to leverage our world-class capabilities in cell line development, cell banking, and cGMP plasmid production."

Centivax's Chief Executive Officer, Jacob Glanville, said, "We are thrilled to announce BioCina as our Master Cell Bank manufacturing partner for the first phase of manufacturing our universal influenza vaccine. BioCina's exemplary expertise and track record in mRNA/LNP MCB, combined with their state-of-the-art facilities, aligns perfectly with Centivax's commitment to innovation and quality. This partnership enables us to leverage BioCina's expertise to ensure the highest standards of vaccine production. Together, we're taking a significant step forward in bringing our universal influenza vaccine to market, with the goal of providing broad, lasting protection against the disease on a global scale."

About BioCina
BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina's first facility in Adelaide, South Australia has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME's having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA, TGA and Health Canada. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including the U.S., Europe, and the Asia Pacific. Australia offers one of the most attractive tax incentives globally (up to 48.5% cash refund), and one of the world's premier trial networks, making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing products. Visit https://biocina.com.

About Centivax
Centivax is a universal vaccine platform technology company founded and led by experts in vaccinology, vaccine regulatory affairs, immunology, and computational bioengineering. The universal vaccine platform intellectual property has demonstrated unprecedented breadth of protection against influenza and coronaviruses. The platform delivers ultra-broad neutralizing titers, HAI titers and in-vivo protection in ferrets, pigs, rats, mice and human immune organoids. Development of the Centivax platform has been financially supported by the Global Health Investment Corporation (GHIC) BARDA venture arm, NFX, BLUE KNIGHT™ J&J/BARDA program, the Bill and Melinda Gates Foundation, the National Institute of Health (NIH), the Naval Medical Research Center, the Walter Reed Army Institute of Research, the Medical Technology Enterprise Consortium, the Department of Defense, and the National Institute for Innovation in Manufacturing Biopharmaceuticals. Centivax is on a mission to accelerate the world's transition to a post-pathogen humanity.

Media Contact
media@biocina.com 

source: BioCina

【你點睇?】新一份預算案公布,多項開源節流措施推出,你認為哪一項措施最能達致改善政府財赤目標?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
3
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
4
財政預算案2025 | 重點文字直播/Youtube直播(稍後送上懶人包)
5
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
6
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
9
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
10
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
11
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
12
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
13
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
14
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
15
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
16
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
17
高息定存 | 信銀國際12個月港元定存高達3.5厘
18
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
19
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
20
民營企業座談會 | 習近平在京出席民營企業座談會
21
David Webb:因病情惡化,將有序結束個人財經網站
22
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
23
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
24
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
25
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
26
港股 | 蕭猷華:恒指升勢可持續?
27
美股收盤 | 美股三大指數收市報跌,道指跌近750點
28
比特幣 | 亞洲時段虛擬貨幣大幅下跌,31萬人爆倉
29
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
30
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

2025-26年度財政預算案

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老